Neurochemical Journal

, Volume 12, Issue 1, pp 64–70 | Cite as

An Analysis of the Behavioral and Neurochemical Effects of Himantane on the Dynamics of the Ethanol-Induced Hyperlocomotor Response in DBA/2 Mice

  • V. S. Kudrin
  • A. V. Nadorova
  • V. B. Narkevich
  • L. G. Kolik
Experimental Articles


We studied the effect of himantane (N-(2-adamantyl)-hexamethyleneimine hydrochloride) on the ethanol-induced hyperlocomotor response in DBA/2 mice. It was found that himantane (20.0 mg/kg, i.p.) per se did not affect the spontaneous locomotor activity but weakened the stimulation of the behavior caused by ethanol (2.0 g/kg, intraperitoneally) after its preliminary single systemic administration. In ex vivo experiments where we evaluated the effect of himantane on the level of monoamines and their metabolites after acute ethanol administration it was shown that himantane has a predominant effect on dopamine and noradrenergic neurotransmitter systems in the striatum in the absence of effects on the serotonergic system.


himantane ethanol hyperlocomotion reaction DBA/2 mice brain structures norepinephrine dopamine HPLC 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Deng, X.S. and Deitrich, R.A., Curr. Drug Abuse Rev., 2008, vol. 1, pp. 3–8.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Karahanian, E., Quintanilla, M.E., Tampier, L., Rivera-Meza, M., Bustamante, D., Gonzalez-Lira, V., Morales, P., Herrera-Marschitz, M., and Israel, Y., Alcohol Clin.Exp. Res., 2011, vol. 35, no. 4, pp. 606–612.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Aragon, C.M., Rogan, F., and Amit, Z., Biochem. Pharmacol., 1992, vol. 44, pp. 93–98.CrossRefPubMedGoogle Scholar
  4. 4.
    Quertemont, E., Tambour, S., and Tirelli, E., Prog. Neurobiol., 2005, vol. 75, no. 4, pp. 247–274.CrossRefPubMedGoogle Scholar
  5. 5.
    Holtzman, S.G. and Schneider, F.H., Life Sci., 1974, vol. 14, no. 7, pp. 1243–1250.CrossRefPubMedGoogle Scholar
  6. 6.
    Sanchis-Segura, C., Miquel, M., Correa, M., and Aragon, C.M., Alcohol, 1999, vol. 19, no. 1, pp. 37–42.CrossRefPubMedGoogle Scholar
  7. 7.
    Manrique, H.M., Miquel, M., and Aragon, C.M., Neuropharmacology, 2006, vol. 51, nos. 7–8, pp. 1137–45.CrossRefPubMedGoogle Scholar
  8. 8.
    Ledesma, J.C., Font, L., and Aragon, C.M., Drug Alcohol Depend., 2012, vol. 124, nos. 1–2, pp. 42–49.CrossRefPubMedGoogle Scholar
  9. 9.
    Shiman, R., Akino, M., and Kaufman, S., J. Biol. Chem., 1971, vol. 216, pp. 1130–1140.Google Scholar
  10. 10.
    Bortolato, M., Chen, K., and Shih, J.C., Adv. Drug Deliv. Rev., 2008, vol. 60, nos. 13–14, pp. 1527–1533.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Cohen, C., Curet, O., Perrault, G., and Sanger, D.J., Pharmacol. Biochem. Behav., 1999, vol. 64, pp. 535–539.CrossRefPubMedGoogle Scholar
  12. 12.
    Kash, T.L., Alcohol, 2012, vol. 46, pp. 303–308.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Sivolap, Yu.P. and Damulin, I.V., Zhurn. Nevrol. Psikhiatr. im. S.S. Korsakova, 2013, vol. 113, no. 6-2, pp. 20–26.Google Scholar
  14. 14.
    Krishnan-Sarin, S., O’Malley, S.S., Franco, N., Cavallo, D.A., Morean, M., Shi, J., Pittman, B., and Krystal, J.H., Alcohol Clin. Exp. Res., 2015, vol. 39, no. 2, pp. 300–307.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Wesemann, W. and Ekenna, O., Arzneimittelforschung, 1982, vol. 32, no. 10, pp. 1241–1243.PubMedGoogle Scholar
  16. 16.
    Val’dman, E.A., Voronina, T.A., and Nerobkova, L.N., Eksper. Klin. Farmakol., 1999, vol. 62, no. 4, pp. 3–6.Google Scholar
  17. 17.
    Seredenin, S.B., Kolik, L.G., and Nadorova, A.V., RF Patent No. 2582966 (2016).Google Scholar
  18. 18.
    Val’dman, E.A., Voronina, T.A., Aksenova, L.N., Buneeva, O.A., and Medvedev, A.E., Eksper. Klin. Farmakol., 2003, vol. 66, no. 5, pp. 3–5.Google Scholar
  19. 19.
    Elshanskaya, M.V., Sobolevskii, A.I., Khodorov, B.I., and Val’dman, E.A., Eksper. Klin. Farmakol., 2001, vol. 64, no. 1, pp. 18–21.Google Scholar
  20. 20.
    Andyarzhanova, E.A., Val’dman, E.A., Kudrin, V.S., Raevskii, K.S., and Voronina, T.A., Eksperim. Klin. Farmakol., 2001, vol. 64, no. 6, pp. 13–16.Google Scholar
  21. 21.
    Abaimov, D.A., Zimin, I.A., Kudrin, V.S., and Kovalev, G.I., Eksper. Klin. Farmakol., 2009, vol. 72, no. 1, pp. 64–67.Google Scholar
  22. 22.
    Melon, L.C. and Boehm, S.L., Alcohol Clin. Exp. Res., 2011, vol. 35, no. 7, pp. 1351–1360.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Nadorova, A.V., Kolik, L.G., Klodt, P.M., Narkevich, V.B., Naplekova, P.L., Kozlovskaya, M.M., Kudrin, V.S., and Seredenin, S.B., Neirokhimiya, 2014, vol. 31, no. 2, pp. 1–7.Google Scholar
  24. 24.
    Saeed, DarM., J. Neural Transm., 1984, vol. 60, nos. 3–4, pp. 283–294.Google Scholar
  25. 25.
    Budygin, E.A., Mathews, T.A., Lapa, G.B., and Jones, S.R., Eur. J. Pharmacol., 2005, vol. 523, nos. 1–3, pp. 40–45.CrossRefPubMedGoogle Scholar
  26. 26.
    Reus, G.Z., Valvassori, S.S., Machado, R.A., Martins, M.R., Gavioli, E.C., and Quevedo, J., Naunyn-Schmiedeberg’s Arch. Pharmacol., 2008, vol. 376, no. 5, pp. 295–300.CrossRefGoogle Scholar
  27. 27.
    Menon, M.K., Vivonia, C.A., and Haddox, V.G., Psychopharmacology (Berl.), 1984, vol. 82, nos. 1–2, pp. 89–92.Google Scholar
  28. 28.
    Ledesma, J.C., Escrig, M.A., Pastor, R., and Aragon, C.M., Pharmacol. Biochem. Behav., 2014, vol. 116, pp. 30–38.CrossRefPubMedGoogle Scholar
  29. 29.
    Duncan, J.W., Zhang, X., Wang, N., Johnson, S., Harris, S., Udemgba, C., Ou, X.M., Youdim, M.B., Stockmeier, C.A., and Wang, J.M., Neuropharmacol., 2016, vol. 105, pp. 329–340.CrossRefGoogle Scholar

Copyright information

© Pleiades Publishing, Ltd. 2018

Authors and Affiliations

  • V. S. Kudrin
    • 1
    • 2
  • A. V. Nadorova
    • 1
  • V. B. Narkevich
    • 1
  • L. G. Kolik
    • 1
  1. 1.Zakusov Institute of PharmacologyMoscowRussia
  2. 2.MoscowRussia

Personalised recommendations